Benzinga | Apr 19, 2021 08:05AM EDT

Ziopharm Oncology Announces First Patient Infused In CD19 RPM CAR-T Phase I Clinical Trial Being Conducted By Joint Venture Partner Eden BioCell

Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing ("RPM") CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics.



The patient was treated at National Taiwan University Hospital under the direction of lead investigator, Dr. Shang-Ju Wu.

The patient's T cells, collected from the patient via apheresis, were genetically engineered utilizing the Company's non-viral Sleeping Beauty transposon transposase system and infused two days after gene transfer.

"We are excited to be conducting this important trial for this experimental treatment," said Dr. Jay Zhang, Chief Executive Officer of TriArm Therapeutics.

The Company and Eden BioCell will provide updates regarding the experimental treatment and other patient data in the second half of the year at appropriate venue(s), including scientific conferences, publications and / or bespoke events that the Company may convene.

About the Trial "Infusion of CD19-Specific Chimeric Antigen Receptor T-cells Produced by Rapid Personalized Manufacture for Patients with Advanced Lymphoid Malignancies"

This is a single center phase I, open-label dose-escalation trial, for patients with relapsed CD19+ leukemias and lymphomas. Up to 24 patients will be enrolled in this trial. The primary endpoint of the trial is to evaluate the safety and tolerability of autologous CD19-specific T cells manufactured using the RPM process.